Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial
Impaired sleep and alertness are some of the most common nonmotor manifestations of Parkinson disease (PD) and currently have only limited treatment options. Light therapy (LT), a widely available treatment modality in sleep medicine, has not been systematically studied in the PD population. To dete...
Uložené v:
| Vydané v: | JAMA neurology Ročník 74; číslo 4; s. 411 - 418 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.04.2017
|
| Predmet: | |
| ISSN: | 2168-6157 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Impaired sleep and alertness are some of the most common nonmotor manifestations of Parkinson disease (PD) and currently have only limited treatment options. Light therapy (LT), a widely available treatment modality in sleep medicine, has not been systematically studied in the PD population.
To determine the safety and efficacy of LT on excessive daytime sleepiness (EDS) associated with PD.
This randomized, placebo-controlled, clinical intervention study was set in PD centers at Northwestern University and Rush University. Participants were 31 patients with PD receiving stable dopaminergic therapy with coexistent EDS, as assessed by an Epworth Sleepiness Scale score of 12 or greater, and without cognitive impairment or primary sleep disorder. Participants were randomized 1:1 to receive bright LT or dim-red LT (controlled condition) twice daily in 1-hour intervals for 14 days. This trial was conducted between March 1, 2007, and October 31, 2012. Data analysis of the intention-to-treat population was conducted from November 1, 2012, through April 30, 2016.
The primary outcome measure was the change in the Epworth Sleepiness Scale score comparing the bright LT with the dim-red LT. Secondary outcome measures included the Pittsburgh Sleep Quality Index score, the Parkinson's Disease Sleep Scale score, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy-derived metrics.
Among the 31 patients (13 males and 18 females; mean [SD] disease duration, 5.9 [3.6] years), bright LT resulted in significant improvements in EDS, as assessed by the Epworth Sleepiness Scale score (mean [SD], 15.81 [3.10] at baseline vs 11.19 [3.31] after the intervention). Both bright LT and dim-red LT were associated with improvements in sleep quality as captured by mean (SD) scores on the Pittsburg Sleep Quality Index (7.88 [4.11] at baseline vs 6.25 [4.27] after bright LT, and 8.87 [2.83] at baseline vs 7.33 [3.52] after dim-red LT) and the Parkinson's Disease Sleep Scale (97.24 [22.49] at baseline vs 106.98 [19.37] after bright LT, and 95.11 [19.86] at baseline vs 99.28 [16.94] after dim-red LT). Bright LT improved several self-reported mean (SD) sleep metrics, including sleep fragmentation (number of overnight awakenings, 1.51 [1.03] at baseline vs 0.92 [0.97] after the intervention), sleep quality (sleep diary score, 3.03 [1.01] at baseline vs 3.53 [0.91] after the intervention), and ease of falling asleep (sleep diary score, 2.32 [0.89] at baseline vs 1.83 [0.88] after the intervention). Light therapy was associated with increased daily physical activity as assessed by actigraphy (average activity [SD] counts, 165.01 [66.87] at baseline vs 194.59 [87.81] after the intervention).
Light therapy was well tolerated and may be a feasible intervention for improving the sleep-wake cycles in patients with PD. Further studies are required to determine optimal parameters of LT for PD.
clinicaltrials.gov Identifier: NCT01338649. |
|---|---|
| AbstractList | Impaired sleep and alertness are some of the most common nonmotor manifestations of Parkinson disease (PD) and currently have only limited treatment options. Light therapy (LT), a widely available treatment modality in sleep medicine, has not been systematically studied in the PD population.
To determine the safety and efficacy of LT on excessive daytime sleepiness (EDS) associated with PD.
This randomized, placebo-controlled, clinical intervention study was set in PD centers at Northwestern University and Rush University. Participants were 31 patients with PD receiving stable dopaminergic therapy with coexistent EDS, as assessed by an Epworth Sleepiness Scale score of 12 or greater, and without cognitive impairment or primary sleep disorder. Participants were randomized 1:1 to receive bright LT or dim-red LT (controlled condition) twice daily in 1-hour intervals for 14 days. This trial was conducted between March 1, 2007, and October 31, 2012. Data analysis of the intention-to-treat population was conducted from November 1, 2012, through April 30, 2016.
The primary outcome measure was the change in the Epworth Sleepiness Scale score comparing the bright LT with the dim-red LT. Secondary outcome measures included the Pittsburgh Sleep Quality Index score, the Parkinson's Disease Sleep Scale score, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy-derived metrics.
Among the 31 patients (13 males and 18 females; mean [SD] disease duration, 5.9 [3.6] years), bright LT resulted in significant improvements in EDS, as assessed by the Epworth Sleepiness Scale score (mean [SD], 15.81 [3.10] at baseline vs 11.19 [3.31] after the intervention). Both bright LT and dim-red LT were associated with improvements in sleep quality as captured by mean (SD) scores on the Pittsburg Sleep Quality Index (7.88 [4.11] at baseline vs 6.25 [4.27] after bright LT, and 8.87 [2.83] at baseline vs 7.33 [3.52] after dim-red LT) and the Parkinson's Disease Sleep Scale (97.24 [22.49] at baseline vs 106.98 [19.37] after bright LT, and 95.11 [19.86] at baseline vs 99.28 [16.94] after dim-red LT). Bright LT improved several self-reported mean (SD) sleep metrics, including sleep fragmentation (number of overnight awakenings, 1.51 [1.03] at baseline vs 0.92 [0.97] after the intervention), sleep quality (sleep diary score, 3.03 [1.01] at baseline vs 3.53 [0.91] after the intervention), and ease of falling asleep (sleep diary score, 2.32 [0.89] at baseline vs 1.83 [0.88] after the intervention). Light therapy was associated with increased daily physical activity as assessed by actigraphy (average activity [SD] counts, 165.01 [66.87] at baseline vs 194.59 [87.81] after the intervention).
Light therapy was well tolerated and may be a feasible intervention for improving the sleep-wake cycles in patients with PD. Further studies are required to determine optimal parameters of LT for PD.
clinicaltrials.gov Identifier: NCT01338649. IMPORTANCEImpaired sleep and alertness are some of the most common nonmotor manifestations of Parkinson disease (PD) and currently have only limited treatment options. Light therapy (LT), a widely available treatment modality in sleep medicine, has not been systematically studied in the PD population.OBJECTIVETo determine the safety and efficacy of LT on excessive daytime sleepiness (EDS) associated with PD.DESIGN, SETTINGS, AND PARTICIPANTSThis randomized, placebo-controlled, clinical intervention study was set in PD centers at Northwestern University and Rush University. Participants were 31 patients with PD receiving stable dopaminergic therapy with coexistent EDS, as assessed by an Epworth Sleepiness Scale score of 12 or greater, and without cognitive impairment or primary sleep disorder. Participants were randomized 1:1 to receive bright LT or dim-red LT (controlled condition) twice daily in 1-hour intervals for 14 days. This trial was conducted between March 1, 2007, and October 31, 2012. Data analysis of the intention-to-treat population was conducted from November 1, 2012, through April 30, 2016.MAIN OUTCOMES AND MEASURESThe primary outcome measure was the change in the Epworth Sleepiness Scale score comparing the bright LT with the dim-red LT. Secondary outcome measures included the Pittsburgh Sleep Quality Index score, the Parkinson's Disease Sleep Scale score, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy-derived metrics.RESULTSAmong the 31 patients (13 males and 18 females; mean [SD] disease duration, 5.9 [3.6] years), bright LT resulted in significant improvements in EDS, as assessed by the Epworth Sleepiness Scale score (mean [SD], 15.81 [3.10] at baseline vs 11.19 [3.31] after the intervention). Both bright LT and dim-red LT were associated with improvements in sleep quality as captured by mean (SD) scores on the Pittsburg Sleep Quality Index (7.88 [4.11] at baseline vs 6.25 [4.27] after bright LT, and 8.87 [2.83] at baseline vs 7.33 [3.52] after dim-red LT) and the Parkinson's Disease Sleep Scale (97.24 [22.49] at baseline vs 106.98 [19.37] after bright LT, and 95.11 [19.86] at baseline vs 99.28 [16.94] after dim-red LT). Bright LT improved several self-reported mean (SD) sleep metrics, including sleep fragmentation (number of overnight awakenings, 1.51 [1.03] at baseline vs 0.92 [0.97] after the intervention), sleep quality (sleep diary score, 3.03 [1.01] at baseline vs 3.53 [0.91] after the intervention), and ease of falling asleep (sleep diary score, 2.32 [0.89] at baseline vs 1.83 [0.88] after the intervention). Light therapy was associated with increased daily physical activity as assessed by actigraphy (average activity [SD] counts, 165.01 [66.87] at baseline vs 194.59 [87.81] after the intervention).CONCLUSIONS AND RELEVANCELight therapy was well tolerated and may be a feasible intervention for improving the sleep-wake cycles in patients with PD. Further studies are required to determine optimal parameters of LT for PD.TRIAL REGISTRATIONclinicaltrials.gov Identifier: NCT01338649. |
| Author | Kuhta, Teresa Videnovic, Aleksandar Marconi, Angelica Klerman, Elizabeth B Zee, Phyllis C Wang, Wei |
| Author_xml | – sequence: 1 givenname: Aleksandar surname: Videnovic fullname: Videnovic, Aleksandar organization: Department of Neurology, Massachusetts General Hospital, Boston 2Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts – sequence: 2 givenname: Elizabeth B surname: Klerman fullname: Klerman, Elizabeth B organization: Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts3Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts – sequence: 3 givenname: Wei surname: Wang fullname: Wang, Wei organization: Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts – sequence: 4 givenname: Angelica surname: Marconi fullname: Marconi, Angelica organization: Department of Neurology, Northwestern University, Chicago, Illinois – sequence: 5 givenname: Teresa surname: Kuhta fullname: Kuhta, Teresa organization: Department of Neurology, Northwestern University, Chicago, Illinois – sequence: 6 givenname: Phyllis C surname: Zee fullname: Zee, Phyllis C organization: Department of Neurology, Northwestern University, Chicago, Illinois |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28241159$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kMtOwzAQRS0EoqX0DxDykk2K7TzssKtaXlIlEASxjCbJhLokcbCTRfl6LLXM5kpX587iXJDTznRIyBVnC84Yv91BCx2O1jQLwXiyiHkqTshU8EQFCY_lhMyd2zF_irEojM7JRCgRcR6nU-Iy3WJFN_prO9Bsixb6Pa2Npe8NYk-hq-ga9oOHDo3u0Dm6dM6UGga__NTDlr6C_dadMx1da4fg8I4u6Zsfm1b_emjV6E6X0NDMamguyVkNjcP5MWfk4-E-Wz0Fm5fH59VyE0Co-BAIVJKzGEImWQUgCsWKOKorrNIKVZ2Wqa94CSiSVHCRYiGKtI6TSoQRSinFjNwc_vbW_IzohrzVrsSm8brM6HKupFAyjHjs0esjOhbeR95b3YLd5_-ixB-L1W4I |
| CitedBy_id | crossref_primary_10_1016_j_cger_2019_09_005 crossref_primary_10_1080_14656566_2024_2422004 crossref_primary_10_1016_j_chest_2020_09_099 crossref_primary_10_1126_scitranslmed_abe7099 crossref_primary_10_3389_fcimb_2021_696554 crossref_primary_10_1016_j_tins_2018_03_002 crossref_primary_10_1186_s12888_025_06915_z crossref_primary_10_1212_WNL_0000000000007090 crossref_primary_10_1007_s40675_023_00249_6 crossref_primary_10_1016_j_heliyon_2024_e24752 crossref_primary_10_1016_S1474_4422_18_30461_7 crossref_primary_10_3389_fnagi_2022_887094 crossref_primary_10_1038_s41398_020_01155_z crossref_primary_10_3390_jcm13226982 crossref_primary_10_1016_j_jamda_2022_10_008 crossref_primary_10_1016_j_neurot_2025_e00728 crossref_primary_10_1111_jsr_70011 crossref_primary_10_3389_fnins_2020_592989 crossref_primary_10_1155_2019_1906271 crossref_primary_10_1016_S1474_4422_24_00170_4 crossref_primary_10_1186_s40035_023_00340_6 crossref_primary_10_7555_JBR_37_20230264 crossref_primary_10_1016_j_jpainsymman_2025_03_034 crossref_primary_10_1007_s12264_021_00711_x crossref_primary_10_1136_jnnp_2018_318810 crossref_primary_10_3390_jpm12020322 crossref_primary_10_1155_2018_5908359 crossref_primary_10_1002_mds_70009 crossref_primary_10_3389_frsle_2023_1302021 crossref_primary_10_1242_bio_059273 crossref_primary_10_3389_fphys_2020_00294 crossref_primary_10_1007_s40675_017_0079_y crossref_primary_10_1016_j_nbd_2025_106791 crossref_primary_10_1172_JCI148286 crossref_primary_10_3390_brainsci14121218 crossref_primary_10_1186_s40478_018_0596_z crossref_primary_10_4103_1673_5374_390970 crossref_primary_10_1007_s12035_024_04400_4 crossref_primary_10_1016_j_ncl_2024_12_008 crossref_primary_10_1093_sleep_zsae055 crossref_primary_10_1097_WCO_0000000000000579 crossref_primary_10_1007_s11818_019_00215_x crossref_primary_10_1371_journal_pone_0292342 crossref_primary_10_3390_antiox12020396 crossref_primary_10_1097_CM9_0000000000001818 crossref_primary_10_1212_WNL_0000000000007078 crossref_primary_10_1007_s00415_020_09845_w crossref_primary_10_5498_wjp_v14_i12_1982 crossref_primary_10_3390_diagnostics12010088 crossref_primary_10_1016_j_nantod_2024_102625 crossref_primary_10_1055_a_2566_4073 crossref_primary_10_1371_journal_pone_0212951 crossref_primary_10_3389_fnagi_2022_1050715 crossref_primary_10_1016_j_neulet_2018_08_015 crossref_primary_10_3389_fnmol_2018_00496 crossref_primary_10_1007_s11910_018_0838_2 crossref_primary_10_1080_07317115_2022_2111014 crossref_primary_10_1515_revneuro_2023_0026 crossref_primary_10_1089_caff_2019_0009 crossref_primary_10_1097_CM9_0000000000001301 crossref_primary_10_3233_JPD_202425 crossref_primary_10_1016_j_buildenv_2024_111587 crossref_primary_10_3233_JHD_230567 crossref_primary_10_3390_biomedicines11082179 crossref_primary_10_1038_s41582_021_00577_7 crossref_primary_10_3233_JAD_200383 crossref_primary_10_3389_fnins_2021_799526 crossref_primary_10_3390_app11209433 crossref_primary_10_1016_j_ncl_2019_04_002 crossref_primary_10_1109_JTEHM_2019_2937957 crossref_primary_10_4103_0366_6999_229889 crossref_primary_10_1038_s41531_025_01009_9 crossref_primary_10_1007_s00415_024_12730_5 crossref_primary_10_1007_s13311_021_01032_7 crossref_primary_10_3389_fnagi_2017_00170 crossref_primary_10_1093_sleep_zsac209 crossref_primary_10_1159_000477094 crossref_primary_10_3389_fphys_2018_01557 crossref_primary_10_1111_ejn_14298 crossref_primary_10_1016_j_sleep_2021_03_035 crossref_primary_10_1212_CON_0000000000001265 crossref_primary_10_3233_JAD_210170 crossref_primary_10_1111_jnc_15286 crossref_primary_10_3233_JPD_212749 crossref_primary_10_1080_07420528_2021_1929281 crossref_primary_10_1016_j_ncl_2019_04_004 crossref_primary_10_1515_tnsci_2020_0130 crossref_primary_10_1016_j_parkreldis_2022_06_009 crossref_primary_10_1002_ana_25897 crossref_primary_10_1002_mdc3_12899 crossref_primary_10_1016_j_jsmc_2021_03_001 crossref_primary_10_1016_S0140_6736_21_00218_X crossref_primary_10_31083_j_fbl2906206 crossref_primary_10_1007_s00415_021_10812_2 crossref_primary_10_1007_s13311_020_00959_7 crossref_primary_10_1016_j_gerinurse_2025_103402 crossref_primary_10_1016_j_jamda_2023_03_007 crossref_primary_10_2147_NSS_S476348 crossref_primary_10_3233_JPD_212775 crossref_primary_10_1016_j_jsmc_2025_06_005 crossref_primary_10_3390_biology10111205 crossref_primary_10_1016_j_jsmc_2025_06_002 crossref_primary_10_2147_NSS_S375098 crossref_primary_10_1016_j_mehy_2025_111759 crossref_primary_10_1016_j_brainresbull_2019_06_013 crossref_primary_10_3389_fendo_2022_1051882 crossref_primary_10_1016_j_neubiorev_2025_106044 crossref_primary_10_3390_s20185171 crossref_primary_10_1016_j_neubiorev_2022_104767 crossref_primary_10_13078_jsm_250016 crossref_primary_10_3389_fneur_2018_00741 crossref_primary_10_4103_0366_6999_229903 crossref_primary_10_1016_j_parkreldis_2024_107149 crossref_primary_10_1016_j_brainres_2017_09_027 crossref_primary_10_1016_S1474_4422_17_30410_6 crossref_primary_10_1146_annurev_psych_022824_043825 crossref_primary_10_1016_j_ncl_2019_12_003 crossref_primary_10_1016_j_parkreldis_2019_02_041 crossref_primary_10_1016_j_parkreldis_2023_105309 crossref_primary_10_1177_0891988720988904 crossref_primary_10_1186_s12883_021_02292_8 crossref_primary_10_1007_s11940_017_0461_6 crossref_primary_10_1007_s00415_019_09651_z crossref_primary_10_1002_acn3_51204 crossref_primary_10_1007_s12264_023_01089_8 crossref_primary_10_1007_s11910_023_01312_z crossref_primary_10_3389_fendo_2024_1307537 crossref_primary_10_1016_j_parkreldis_2025_107776 crossref_primary_10_1007_s13311_020_00938_y crossref_primary_10_1111_jpi_12759 crossref_primary_10_1007_s10517_019_04677_9 crossref_primary_10_1038_s41386_019_0448_y crossref_primary_10_3390_ijms24032407 crossref_primary_10_1016_j_pneurobio_2019_01_002 crossref_primary_10_4103_1673_5374_228764 crossref_primary_10_1007_s13760_019_01214_3 crossref_primary_10_1080_14737175_2021_1883428 crossref_primary_10_1111_ejn_14362 crossref_primary_10_3233_JPD_230228 crossref_primary_10_1016_j_yebeh_2021_107867 crossref_primary_10_1097_CM9_0000000000002276 crossref_primary_10_1007_s00592_021_01712_y crossref_primary_10_1016_j_arr_2024_102232 crossref_primary_10_1111_apha_13966 crossref_primary_10_1038_s41598_020_64645_6 crossref_primary_10_1007_s11910_022_01220_8 crossref_primary_10_3389_fphys_2022_873237 crossref_primary_10_1080_07853890_2024_2381220 crossref_primary_10_1093_sleep_zsae285 crossref_primary_10_3389_fnhum_2023_1107061 crossref_primary_10_3390_brainsci13020275 crossref_primary_10_1016_j_sleep_2018_01_001 crossref_primary_10_1016_j_sleep_2024_10_008 crossref_primary_10_1186_s13256_024_04812_9 crossref_primary_10_1002_pchj_215 crossref_primary_10_1155_2018_5868570 crossref_primary_10_3390_brainsci13081202 crossref_primary_10_1111_apha_13970 crossref_primary_10_1038_s41422_023_00920_1 crossref_primary_10_1007_s00415_023_12073_7 crossref_primary_10_1016_j_celrep_2025_115865 crossref_primary_10_1093_sleep_zsae036 crossref_primary_10_1155_2022_6701519 crossref_primary_10_3389_fnins_2024_1337616 crossref_primary_10_1080_07420528_2019_1604539 crossref_primary_10_1097_PSY_0000000000000949 crossref_primary_10_1002_ana_25853 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamaneurol.2016.5192 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2168-6157 |
| EndPage | 418 |
| ExternalDocumentID | 28241159 |
| Genre | Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: K24 HL105664 – fundername: NHLBI NIH HHS grantid: R01 HL114088 – fundername: NINDS NIH HHS grantid: K23 NS072283 – fundername: NHLBI NIH HHS grantid: R01 HL128538 – fundername: NINDS NIH HHS grantid: R01 NS099055 – fundername: NIA NIH HHS grantid: P01 AG009975 |
| GroupedDBID | 0R~ 4.4 53G AAGZG ABIVO ABJNI ACDNT ACGFS ACPRK ADBBV ADHGD AENEX AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EJD EMOBN EX3 H13 NPM OB2 OBH OHH OVD PQQKQ RAJ SV3 TEORI WOW 7X8 |
| ID | FETCH-LOGICAL-a381t-2e87105a3070daa2b80b54fded9de8f9c92b81cae2692129eb2b9f56d234e7772 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 195 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000398679600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Thu Jul 10 20:25:13 EDT 2025 Thu Apr 03 06:55:55 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a381t-2e87105a3070daa2b80b54fded9de8f9c92b81cae2692129eb2b9f56d234e7772 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 28241159 |
| PQID | 1872873415 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1872873415 pubmed_primary_28241159 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-04-01 |
| PublicationDateYYYYMMDD | 2017-04-01 |
| PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA neurology |
| PublicationTitleAlternate | JAMA Neurol |
| PublicationYear | 2017 |
| References | 28241156 - JAMA Neurol. 2017 Apr 1;74(4):387-388 28806434 - JAMA Neurol. 2017 Oct 1;74(10):1268-1269 28806435 - JAMA Neurol. 2017 Oct 1;74(10):1267-1268 |
| References_xml | – reference: 28806434 - JAMA Neurol. 2017 Oct 1;74(10):1268-1269 – reference: 28806435 - JAMA Neurol. 2017 Oct 1;74(10):1267-1268 – reference: 28241156 - JAMA Neurol. 2017 Apr 1;74(4):387-388 |
| SSID | ssj0000800434 |
| Score | 2.609656 |
| Snippet | Impaired sleep and alertness are some of the most common nonmotor manifestations of Parkinson disease (PD) and currently have only limited treatment options.... IMPORTANCEImpaired sleep and alertness are some of the most common nonmotor manifestations of Parkinson disease (PD) and currently have only limited treatment... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 411 |
| SubjectTerms | Actigraphy Adult Aged Disability Evaluation Disorders of Excessive Somnolence - etiology Disorders of Excessive Somnolence - therapy Female Humans Male Middle Aged Parkinson Disease - complications Patient Compliance Phototherapy - methods Retrospective Studies Self Report Severity of Illness Index Visual Analog Scale |
| Title | Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28241159 https://www.proquest.com/docview/1872873415 |
| Volume | 74 |
| WOSCitedRecordID | wos000398679600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbyudnezeXiRYi0ebClasbeS3SRYqLvVrYL-eifJtp4EwcsewgaWzOzMN_nmgdCZSQlhMROBjC3NmEYqSDMWBpwmmQGPa2TDuGETrNvlg4HoVRduZZVWObOJzlCrIrN35BchZwDuweYmV5PXwE6NsuxqNUJjEdVigDI2pYsN-PyOxaIhEpN5xZxvNuQaRVrWIaTniedAf8GWzse01__7dRtorUKXuOnVYRMt6HwLrXQq_nwblbbiQ-E7G5Hjvm8ogAG24oex1hMsc4Vb8tPOm_crLicez0QIO59G02dsK6Vd0RhueXrnEjfxPWwuXkZf8FLVa3SM-1a7d9Bj-6Z_fRtUYxdAXjycBpGGIKqRSGsNlJRRyhtpQozSSijNjcgELIWZ1BEV4PgExOapMAlVUUw0A7S-i5byItf7CGexgPhKcmIgzItpyBWlOtGGRYRyrmUdnc6OcwhqbbkKEE_xXg5_DrSO9rxMhhPff2MIUSIBICsO_rD7EK1G1hG7XJsjVDPwU-tjtJx9TEfl24nTF3h2e51vv_HMuw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Timed+Light+Therapy+for+Sleep+and+Daytime+Sleepiness+Associated+With+Parkinson+Disease%3A+A+Randomized+Clinical+Trial&rft.jtitle=JAMA+neurology&rft.au=Videnovic%2C+Aleksandar&rft.au=Klerman%2C+Elizabeth+B&rft.au=Wang%2C+Wei&rft.au=Marconi%2C+Angelica&rft.date=2017-04-01&rft.eissn=2168-6157&rft.volume=74&rft.issue=4&rft.spage=411&rft.epage=418&rft_id=info:doi/10.1001%2Fjamaneurol.2016.5192&rft.externalDBID=NO_FULL_TEXT |